Shopping Cart 0
Cart Subtotal
AED 0

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Johnson & Johnson (J&J) researches and develops, and manufactures and sells a range of pharmaceutical products, medical devices and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in baby care, oral care, beauty, over-the-counter (OTC) pharmaceutical, women's health and wound care categories; and medical devices for use in the cardiovascular, orthopedic, surgery, diabetes care and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

Johnson & Johnson (JNJ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 13

List of Figures 20

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 21

Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 22

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 23

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 24

Johnson & Johnson, Medical Devices Deals, 2012 to YTD 2018 26

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 28

Johnson & Johnson, Pharmaceuticals & Healthcare, Deal Details 62

Asset Purchase 62

Janssen Pharma Acquires CERC-501 from Cerecor 62

Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 63

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 64

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 66

Venture Financing 67

Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 67

PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 69

ApoGen Biotech Raises Additional USD4 Million in Series A Financing 71

Magnolia Neurosciences Raises USD31 Million in Series A Venture Financing 73

Evolve BioSystems Raises USD40 Million in Series C Financing 75

Syndesi Therapeutics Raises USD21 Million in Series A Financing 77

On Target Labs Raises USD40 Million in Series B Financing 79

BeneVir Biopharm Raises USD2 Million in Venture Financing 80

Fusion Pharma Raises Additional USD17 Million in Series A Financing 81

XW Labs Raises USD17.5 Million in Series B Financing 83

Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 84

E-scape Bio Raises Additional USD8 Million in Series A Financing 86

DayTwo Secures USD12 Million in Series A Funding 88

DayTwo Raises USD12 Million in Series A Financing 89

Aragon Pharmaceuticals Raises USD22 Million in Series B Round of Financing 90

Biomx Raises USD24 Million in Series A Venture Financing 91

Pulmocide Raises USD30.4 Million in Series B Financing 93

Fusion Pharma Raises USD19 Million in Series A Financing 95

SuperX Raises USD11 Million in Series A Financing 96

Caelus Health Raises USD2.7 Million in Series A Financing 97

ApoGen Biotech Raises USD7 Million in Series A Financing 98

ReVision Optics Raises USD32 Million in Venture Financing 100

Blackthorn Therapeutics Raises USD40 Million in Series A Financing 102

BeneVir Biopharm Raises USD3 Million in Venture Financing 104

V-Wave Raises USD28 Million in Venture Financing 105

Lodo Therapeutics Raises USD17 Million in Series A Financing 106

Aelix Therapeutics Raises USD12.7 Million in Series A Financing 108

Petra Pharma Raises USD48 Million in Series A Financing 109

Protekt Therapeutics Raises More Than USD2 Million in Financing 111

Navitor Pharma Raises USD33 Million in Series B Financing 112

First Aid Shot Therapy Raises USD24 Million in Series C Financing 114

PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 115

Asceneuron Raises USD30.6 Million in Series A Financing 116

Merus Raises USD46.4 Million in First Tranche of Series C Financing 118

E-scape Bio Raises USD55 Million in Series A Financing 120

Alligator Bioscience to Raise Funds through Venture Financing 122

Protagonist Therapeutics Raises USD40 Million in Series C Financing 123

PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 125

Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 127

BeneVir Biopharm Raises Funds through Series A Financing 128

Tetra Discovery Raises Funds through Venture Financing 129

XW Labs Raises USD5.5 Million in Series A Financing 130

Inviata Raises USD6.5 Million in Venture Financing 131

ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 132

Ascelegen Therapeutics Raises Funds through Venture Financing 133

Padlock Therapeutics Raises Funds through Series A Financing 134

Navitor Pharma Raises USD24 Million in Series A Financing 135

Aduro BioTech Raises USD55 Million in Series C Financing 137

Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 138

Assembly Pharma Raises Funds Through Seed Financing 139

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 140

Covagen Raises USD 50.3 Million In Series B Financing 141

Novira Therapeutics Raises USD 28 Million In Series A Financing 143

SutroVax Raises Funds Through Initial Financing Round 145

TopiVert Raises USD28 Million in Venture Financing 146

TopiVert Raises USD 7.4 Million In Venture Financing 148

Pulmocide Raises USD 27.4 Million In Series A Financing 150

Biocartis Raises USD 40.5 Million In Series E Financing 152

Merus Raises USD 42 Million In Extended Series B Financing 154

Rodin Therapeutics Raises Funds Through Seed Financing 156

Vedanta Biosciences Raises Funds Through Venture Financing 157

XO1 Raises USD11 Million in Venture Financing 158

X01 Raises USD 11 Million In Series A Financing 159

Catalyst Biosciences Secures USD5.07 Million in Venture Funding 160

Novira Therapeutics Secures USD25 Million in Venture Funding 162

Aquinox Pharma Raises USD 18 Million In Series C Financing 163

Biocartis Raises USD 44.7 Million In Series D Financing 164

Genocea Biosciences Raises USD 30 Million In Series C Financing 166

Aragon Pharma Raises USD 50 Million In Series D Financing 168

PhaseBio Pharma Raises Additional USD 23 Million In The Third Tranche Of Series B Financing Round 169

Celladon Raises Additional USD 10 Million In Series D Financing 171

Direct Flow Medical Secures USD0.28 Million in Venture Funding 173

Coherex Medical Secures USD16.5 Million in Venture Funding 174

Aragon Pharma Raises USD 42 Million In Series C Financing 175

Private Equity 176

Johnson & Johnson Innovation-JJDC to Invest USD75 Million in Arrowhead Pharma 176

Platinum Equity Acquires LifeScan from Johnson & Johnson for USD2.1 Billion 178

Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 179

Partnerships 180

Janssen Amends Licensing Agreement with Gilead for STR 180

Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 181

Janssen Pharma to Enter into Research and Option Agreement with Arrowhead Pharma 182

Janssen Vaccines & Prevention, CEPI and Jenner Institute Enter into Partnership 183

RespireRx Pharma Enters into Agreement Noramco 184

Merck Enters into Co-Development Agreement with Xian-Janssen Pharma 185

GenomeDx Biosciences Enters into Agreement with Janssen Pharma 186

Noramco and SPI Pharma Enter into Agreement 187

Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 188

Janssen Pharma to Enter into Agreement with Pharmstandard 189

Aldeyra Therapeutics Enters into Research Agreement with Janssen Research & Development 190

Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 191

Janssen Biotech Enters into Research Agreement with Koch Institute for Integrative Cancer Research 192

Johnson & Johnson Innovation and Janssen Biotech Enter into Partnership with Monash University 193

Janssen Pharma Enters into Research Partnership with Beacon Discovery 194

Johnson & Johnson Innovation, Johnson & Johnson Consumer Enter into Partnership with Dermala 195

Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 196

Johnson & Johnson Innovation, Johnson & Johnson Consumer and Janssen Research & Development Enter into Research Partnership with Holobiome 197

Johnson & Johnson Innovation, Janssen Research & Development Enter into Partnership with Taiwan Industrial Technology Research Institute 198

Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 199

Taiho Pharma Enters into Co-Marketing Agreement with Janssen Pharma 200

Genomic Health Enters into Research Agreement with Janssen Pharma 201

BioMed X Enters into Agreement with Janssen Research & Development 202

Cerveau Technologies Enters into Agreement with Janssen Pharma 203

Janssen Research & Development Enters into Agreement with U.S. Department of Health 204

Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 205

Johnson & Johnson to Enter into Agreement with Institute of Microbial Technology 206

Proteros biostructures Enters into Research Agreement with Janssen Biotech 207

University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 208

Idorsia and Janssen Biotech to Enter into option Agreement 209

Monash University Enters into Research Agreement with Janssen Biotech 210

Phagelux Enters into Agreement with Johnson & Johnson Consumer 211

Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 212

PeptiDream Enters into Agreement with Janssen Pharma 213

Janssen Pharma Enters into Partnership with Premier 214

Renova Therapeutics Enters into Agreement with Janssen Pharma 215

Mitsubishi Tanabe Pharma Expands Co-Promotion Agreement with Janssen Pharma 216

Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 217

Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 218

Janssen Research & Development Enters into Agreement with ChemDiv 219

DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 220

Enamine Expands Agreement with Actelion 221

Karolinska Institutet Partners with Johnson & Johnson Companies 222

Janssen Biotech Enters into Partnership with Bristol-Myers 223

Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 224

Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 225

Janssen Pharma Enters into Partnership with Bird Rock Bio 226

Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 227

Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 228

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 229

HitGen Enters into Agreement with Janssen Biotech 230

Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 231

Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 232

Philogen Enters Into Collaboration Agreement With Janssen Biotech 233

Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 234

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 235

Amyris Enters into Research Agreement with Janssen Biotech 236

Janssen Research & Development Enters into Agreement with Genentech 237

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 238

DiamiR Enters into Research Agreement with Janssen Pharma 239

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 240

Janssen Biotech Enters into Agreement with HUB foundation 241

Janssen Pharma Enters into Agreement with University of Pennsylvania 242

Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 243

Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 244

Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 245

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 246

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 247

Janssen Pharma Enters into Agreement with University of California, San Diego 248

Enterome Bioscience Enters into Research Agreement with Janssen Biotech 249

Johnson & Johnson Consumer Enters into Agreement with BioMed X 250

Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 251

Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 252

Janssen Biotech Enters into Agreement with Eureka Therapeutics 253

Intrexon Enters into Research Agreement with Janssen Pharma 254

Cypralis Enters into Research Agreement with Janssen Pharma 255

Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 256

Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 257

SynAging Extends Agreement with Actelion Pharma 258

ViroGin Biotech Enters into With Johnson & Johnson Innovation and Janssen Biotech 259

Nuevolution Enters into Discovery Agreement with Janssen Biotech 260

enGene Enters into Agreement with Janssen Biotech 261

OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 262

BlinkBio Enters into Discovery Agreement with Janssen Pharma 263

UbiVac Enters into Agreement with Janssen Biotech 264

Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 265

Nextera Enters into Research Agreement with Janssen Biotech 266

Handok Enters into Agreement with Actelion Pharmaceuticals 267

Actelion Forms Joint Venture with Max Planck Society 268

Johnson & Johnson Enters into Agreement with University of the Witwatersrand 269

Janssen Cilag Enters into Agreement with UniQuest 270

Johnson & Johnson Innovation Enters into Research Agreement with Washington University 271

Janssen Biotech Enters into Research Agreement with Emulate 272

Johnson & Johnson Innovation Partners with Lead Discovery Center 273

NeurOp Enters into Research Agreement with Janssen Pharma 274

AC Immune Enters into Research Agreement with Janssen Pharma 275

X-Chem Expands Agreement with Janssen Biotech 276

Vectura Enters into Development and License Agreement with Janssen Biotech 277

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 278

Sevion Therapeutics Enters into Discovery Agreement with CNA Development 279

Atreca Enters into Research Agreement with Janssen Biotech 280

Vaccinex Enters into Research Agreement with Janssen Research & Development 281

Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 282

Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 283

Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 284

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 285

Alector Enters Into Research Agreement With Janssen Pharma 286

University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 287

Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 288

Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 289

Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 290

Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 291

Evotec Enters Into Co-Development Agreement With Johnson & Johnson 292

ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 293

AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 294

Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 295

DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 296

Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 297

ex scientia Enters into Agreement with Janssen Research & Development 299

Mellitech Enters into Agreement with Janssen Pharma 300

Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 301

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 302

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 303

Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 304

Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 305

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 306

Open Monoclonal Expands Agreement with CNA Development 307

Beactica Enters Into Research Agreement With Janssen Research & Development 308

Janssen-Cilag Enters Into Research Agreement With University of Melbourne 309

Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 310

Artes Biotechnology Enters Into Co-Development Agreement With Crucell 311

Selventa Enters Into Co-Development Agreement With Janssen Research & Development 312

Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland 313

Dendright Enters Into Research Agreement With Janssen-Cilag 314

FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 315

Licensing Agreements 316

Janssen Pharma to Enter into Licensing Agreement with Arrowhead Pharma 316

Immune Biosolutions Enters into Licensing Agreement with Janssen Biotech 318

Macleods Pharma May Enter into Licensing Agreement with Johnson & Johnson 319

Janssen Biotech Enters into Licensing Agreement with Nuevolution 320

Janssen Biotech Enters into Licensing Agreement with Legend Biotech 321

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 322

Janssen Biotech Enters into Licensing Agreement with Zymeworks 323

Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland 324

Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 325

Janssen Pharma Enters into Licensing Agreement with St Vincents Institute of Medical Research 327

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 328

Pulmatrix Enters into Licensing Agreement with RespiVert 329

Janssen Biotech Enters into Licensing Agreement with Trianni 330

Janssen Biotech Enters into Licensing Agreement with Ablexis 331

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 332

Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 334

CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 335

OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 336

BenevolentAI Enters into Licensing Agreement with Janssen Pharma 337

Actelion Enters into Licensing Agreement with ReveraGen BioPharma 338

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 339

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 341

Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 343

GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 344

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 345

Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 346

Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 347

Janssen Biotech Enters into Licensing agreement with Tesaro 348

ViaCyte Enters into Licensing Agreement with Janssen Biotech 349

Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 350

Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 351

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 352

Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 353

Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 354

Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 355

Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 356

Poseida Therapeutics Enters into Licensing Agreement with Janssen 357

Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 358

GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 359

Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 360

Infirst Healthcare Enters into Licensing Agreement with McNeil Consumer Pharma 361

Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 362

Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 363

Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 364

AC Immune Enters into Licensing Agreement with Janssen Pharma 365

Janssen Expands Licensing Agreement with Gilead 366

Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 367

Kura Oncology Amends Licensing Agreement with Janssen Pharma 369

Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 371

Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 372

Janssen Pharma Acquires XO1 509

Valneva Acquires Crucell Sweden for USD54 Million 510

Tetraphase Pharma May Sell Itself 511

Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 513

Cilag Acquires Covagen 515

Novartis Acquires CoStim Pharma 516

Actelion Completes Acquisition Of Ceptaris Therapeutics For USD 250 Million 518

Johnson & Johnson Completes Acquisition Of Aragon Pharma For USD1 Billion 521

Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 523

Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 524

Johnson & Johnson Completes Acquisition Of Shanghai Elsker For Mother & Baby 526

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 528

Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 530

Janssen-Cilag Acquires CorImmun 531

Johnson & Johnson-Key Competitors 533

Johnson & Johnson-Key Employees 534

Johnson & Johnson-Locations And Subsidiaries 535

Head Office 535

Other Locations & Subsidiaries 535

Recent Developments 554

Strategy And Business Planning 554

Oct 03, 2018: J&J concludes sale of LifeScan to Platinum Equity for $2.1bn 554

Financial Announcements 555

Jul 17, 2018: Johnson & Johnson Reports 2018 Second-Quarter Results 555

Apr 17, 2018: Johnson & Johnson Reports 2018 First-Quarter Results 557

Jan 23, 2018: Johnson & Johnson Reports 2017 Fourth-Quarter Results 559

Oct 17, 2017: Johnson & Johnson Reports 2017 Third-Quarter Results 561


List Of Figure

List of Figures

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 21

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 22

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 23

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 24

Johnson & Johnson, Medical Devices Deals, 2012 to YTD 2018 26


List Of Table

List of Tables

Johnson & Johnson, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 21

Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 22

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 23

Johnson & Johnson, Deals By Therapy Area, 2012 to YTD 2018 24

Johnson & Johnson, Medical Devices Deals, 2012 to YTD 2018 26

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 28

Janssen Pharma Acquires CERC-501 from Cerecor 62

Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 63

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 64

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 66

Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 67

PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 69

ApoGen Biotech Raises Additional USD4 Million in Series A Financing 71

Magnolia Neurosciences Raises USD31 Million in Series A Venture Financing 73

Evolve BioSystems Raises USD40 Million in Series C Financing 75

Syndesi Therapeutics Raises USD21 Million in Series A Financing 77

On Target Labs Raises USD40 Million in Series B Financing 79

BeneVir Biopharm Raises USD2 Million in Venture Financing 80

Fusion Pharma Raises Additional USD17 Million in Series A Financing 81

XW Labs Raises USD17.5 Million in Series B Financing 83

Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 84

E-scape Bio Raises Additional USD8 Million in Series A Financing 86

DayTwo Secures USD12 Million in Series A Funding 88

DayTwo Raises USD12 Million in Series A Financing 89

Aragon Pharmaceuticals Raises USD22 Million in Series B Round of Financing 90

Biomx Raises USD24 Million in Series A Venture Financing 91

Pulmocide Raises USD30.4 Million in Series B Financing 93

Fusion Pharma Raises USD19 Million in Series A Financing 95

SuperX Raises USD11 Million in Series A Financing 96

Caelus Health Raises USD2.7 Million in Series A Financing 97

ApoGen Biotech Raises USD7 Million in Series A Financing 98

ReVision Optics Raises USD32 Million in Venture Financing 100

Blackthorn Therapeutics Raises USD40 Million in Series A Financing 102

BeneVir Biopharm Raises USD3 Million in Venture Financing 104

V-Wave Raises USD28 Million in Venture Financing 105

Lodo Therapeutics Raises USD17 Million in Series A Financing 106

Aelix Therapeutics Raises USD12.7 Million in Series A Financing 108

Petra Pharma Raises USD48 Million in Series A Financing 109

Protekt Therapeutics Raises More Than USD2 Million in Financing 111

Navitor Pharma Raises USD33 Million in Series B Financing 112

First Aid Shot Therapy Raises USD24 Million in Series C Financing 114

PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 115

Asceneuron Raises USD30.6 Million in Series A Financing 116

Merus Raises USD46.4 Million in First Tranche of Series C Financing 118

E-scape Bio Raises USD55 Million in Series A Financing 120

Alligator Bioscience to Raise Funds through Venture Financing 122

Protagonist Therapeutics Raises USD40 Million in Series C Financing 123

PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 125

Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 127

BeneVir Biopharm Raises Funds through Series A Financing 128

Tetra Discovery Raises Funds through Venture Financing 129

XW Labs Raises USD5.5 Million in Series A Financing 130

Inviata Raises USD6.5 Million in Venture Financing 131

ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 132

Ascelegen Therapeutics Raises Funds through Venture Financing 133

Padlock Therapeutics Raises Funds through Series A Financing 134

Navitor Pharma Raises USD24 Million in Series A Financing 135

Aduro BioTech Raises USD55 Million in Series C Financing 137

Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 138

Assembly Pharma Raises Funds Through Seed Financing 139

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 140

Covagen Raises USD 50.3 Million In Series B Financing 141

Novira Therapeutics Raises USD 28 Million In Series A Financing 143

SutroVax Raises Funds Through Initial Financing Round 145

TopiVert Raises USD28 Million in Venture Financing 146

TopiVert Raises USD 7.4 Million In Venture Financing 148

Pulmocide Raises USD 27.4 Million In Series A Financing 150

Biocartis Raises USD 40.5 Million In Series E Financing 152

Merus Raises USD 42 Million In Extended Series B Financing 154

Rodin Therapeutics Raises Funds Through Seed Financing 156

Vedanta Biosciences Raises Funds Through Venture Financing 157

XO1 Raises USD11 Million in Venture Financing 158

X01 Raises USD 11 Million In Series A Financing 159

Catalyst Biosciences Secures USD5.07 Million in Venture Funding 160

Novira Therapeutics Secures USD25 Million in Venture Funding 162

Aquinox Pharma Raises USD 18 Million In Series C Financing 163

Biocartis Raises USD 44.7 Million In Series D Financing 164

Genocea Biosciences Raises USD 30 Million In Series C Financing 166

Aragon Pharma Raises USD 50 Million In Series D Financing 168

PhaseBio Pharma Raises Additional USD 23 Million In The Third Tranche Of Series B Financing Round 169

Celladon Raises Additional USD 10 Million In Series D Financing 171

Direct Flow Medical Secures USD0.28 Million in Venture Funding 173

Coherex Medical Secures USD16.5 Million in Venture Funding 174

Aragon Pharma Raises USD 42 Million In Series C Financing 175

Johnson & Johnson Innovation-JJDC to Invest USD75 Million in Arrowhead Pharma 176

Platinum Equity Acquires LifeScan from Johnson & Johnson for USD2.1 Billion 178

Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 179

Janssen Amends Licensing Agreement with Gilead for STR 180

Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 181

Janssen Pharma to Enter into Research and Option Agreement with Arrowhead Pharma 182

Janssen Vaccines & Prevention, CEPI and Jenner Institute Enter into Partnership 183

RespireRx Pharma Enters into Agreement Noramco 184

Merck Enters into Co-Development Agreement with Xian-Janssen Pharma 185

GenomeDx Biosciences Enters into Agreement with Janssen Pharma 186

Noramco and SPI Pharma Enter into Agreement 187

Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 188

Janssen Pharma to Enter into Agreement with Pharmstandard 189

Aldeyra Therapeutics Enters into Research Agreement with Janssen Research & Development 190

Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 191

Janssen Biotech Enters into Research Agreement with Koch Institute for Integrative Cancer Research 192

Johnson & Johnson Innovation and Janssen Biotech Enter into Partnership with Monash University 193

Janssen Pharma Enters into Research Partnership with Beacon Discovery 194

Johnson & Johnson Innovation, Johnson & Johnson Consumer Enter into Partnership with Dermala 195

Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 196

Johnson & Johnson Innovation, Johnson & Johnson Consumer and Janssen Research & Development Enter into Research Partnership with Holobiome 197

Johnson & Johnson Innovation, Janssen Research & Development Enter into Partnership with Taiwan Industrial Technology Research Institute 198

Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 199

Taiho Pharma Enters into Co-Marketing Agreement with Janssen Pharma 200

Genomic Health Enters into Research Agreement with Janssen Pharma 201

BioMed X Enters into Agreement with Janssen Research & Development 202

Cerveau Technologies Enters into Agreement with Janssen Pharma 203

Janssen Research & Development Enters into Agreement with U.S. Department of Health 204

Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 205

Johnson & Johnson to Enter into Agreement with Institute of Microbial Technology 206

Proteros biostructures Enters into Research Agreement with Janssen Biotech 207

University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 208

Idorsia and Janssen Biotech to Enter into option Agreement 209

Monash University Enters into Research Agreement with Janssen Biotech 210

Phagelux Enters into Agreement with Johnson & Johnson Consumer 211

Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 212

PeptiDream Enters into Agreement with Janssen Pharma 213

Janssen Pharma Enters into Partnership with Premier 214

Renova Therapeutics Enters into Agreement with Janssen Pharma 215

Mitsubishi Tanabe Pharma Expands Co-Promotion Agreement with Janssen Pharma 216

Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 217

Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 218

Janssen Research & Development Enters into Agreement with ChemDiv 219

DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 220

Enamine Expands Agreement with Actelion 221

Karolinska Institutet Partners with Johnson & Johnson Companies 222

Janssen Biotech Enters into Partnership with Bristol-Myers 223

Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 224

Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 225

Janssen Pharma Enters into Partnership with Bird Rock Bio 226

Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 227

Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 228

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 229

HitGen Enters into Agreement with Janssen Biotech 230

Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 231

Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 232

Philogen Enters Into Collaboration Agreement With Janssen Biotech 233

Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 234

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 235

Amyris Enters into Research Agreement with Janssen Biotech 236

Janssen Research & Development Enters into Agreement with Genentech 237

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 238

DiamiR Enters into Research Agreement with Janssen Pharma 239

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 240

Janssen Biotech Enters into Agreement with HUB foundation 241

Janssen Pharma Enters into Agreement with University of Pennsylvania 242

Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 243

Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 244

Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 245

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 246

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 247

Janssen Pharma Enters into Agreement with University of California, San Diego 248

Enterome Bioscience Enters into Research Agreement with Janssen Biotech 249

Johnson & Johnson Consumer Enters into Agreement with BioMed X 250

Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 251

Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 252

Janssen Biotech Enters into Agreement with Eureka Therapeutics 253

Intrexon Enters into Research Agreement with Janssen Pharma 254

Cypralis Enters into Research Agreement with Janssen Pharma 255

Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 256

Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 257

SynAging Extends Agreement with Actelion Pharma 258

ViroGin Biotech Enters into With Johnson & Johnson Innovation and Janssen Biotech 259

Nuevolution Enters into Discovery Agreement with Janssen Biotech 260

enGene Enters into Agreement with Janssen Biotech 261

OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 262

BlinkBio Enters into Discovery Agreement with Janssen Pharma 263

UbiVac Enters into Agreement with Janssen Biotech 264

Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 265

Nextera Enters into Research Agreement with Janssen Biotech 266

Handok Enters into Agreement with Actelion Pharmaceuticals 267

Actelion Forms Joint Venture with Max Planck Society 268

Johnson & Johnson Enters into Agreement with University of the Witwatersrand 269

Janssen Cilag Enters into Agreement with UniQuest 270

Janssen-Cilag Acquires CorImmun 531

Johnson & Johnson, Key Competitors 533

Johnson & Johnson, Key Employees 534

Johnson & Johnson, Subsidiaries 535

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Johnson & Johnson, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.